药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02269 药明生物

交易中 08-07 14:40:14

45.200

+3.820

+9.23%

最高45.280	最低41.020	成交量5,537万
今开41.360	昨收41.380	日振幅10.29%
总市值1,873亿	流通市值1,873亿	总股本41.44亿
成交额24.34亿	换手率1.34%	流通股本41.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":45.2,"timestamp":1786084812145,"preClose":41.38,"halted":0,"volume":55367487,"delay":0,"changeRate":0.09231512808119864,"floatShares":4144000000,"shares":4144000000,"eps":1.3496598706853271,"marketStatus":"交易中","change":3.82,"latestTime":"08-07 14:40:14","open":41.36,"high":45.28,"low":41.02,"amount":2433812654,"amplitude":0.102948,"askPrice":45.2,"askSize":2500,"bidPrice":45.18,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":1.3496598706853271,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786090200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":41.38,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":2.18704,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.5201,"impliedVolPercentile":0.5388},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2657693089","title":"港股异动 | 创新药概念多数走高 创新药企陆续迎业绩窗口 后续学术会议有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657693089?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:24","pubTimestamp":1786073069,"startTime":"0","endTime":"0","summary":"消息面上，近期多家创新药企业陆续发布业绩相关公告。从百济神州净利润同比增超6倍，到药明康德大幅上调全年收入指引，再到信达生物、荣昌生物各自兑现增长逻辑，创新药产业链正迎来\"业绩落地+催化密集\"的共振窗口。值得一提的是，海外顶级医学会议临床数据披露有望成为短期核心催化。其次，该行长期看好国产创新药发展趋势，行业景气度向上，出海持续演绎，后续学术会议陆续召开，临床数据有望读出，带来密集催化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","LU3063872942.SGD","SG9999002463.SGD","06978","LU0051755006.USD","MEDX","02269","LU1720050803.USD","BK1588","02268","01672","09688","LU0348825331.USD","LU2488822045.USD","LU0307460666.USD","LU0327786744.USD","LU0348735423.USD","LU0359202008.SGD","LU1880383366.USD","LU0417516738.SGD","LU0417516902.SGD","LU0979878070.USD","IBBQ","LU0823426308.USD","KCAI","159992","LU1794554557.SGD","BK1574","LU0039217434.USD","LU0819121731.USD","KURE","LU0181495838.USD","07666","BK1161","LU1242518931.SGD","LNGR","BK1515","LU0359201612.USD","VXUS","BK1589","LU0516422366.SGD","LU0823426480.USD","LU0708995583.HKD","LU0856984785.SGD","LU0043850808.USD","BK1521","LU0572944931.SGD","SG9999002562.SGD","LU0456846285.SGD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660793","title":"医药股强势走强 再鼎医药（09688）涨13.97%、药明生物（02269）涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660793","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657660793?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:06","pubTimestamp":1786068387,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股强势走强，再鼎医药 涨13.97%，药明生物涨5.41%，药明合联涨4.78%，药明康德涨4.73%，百济神州涨3.66%，荣昌生物涨2.33%，泰格医药涨2.07%。。国信证券表示，2026年版国家基本药物目录近期正式发布，这是目录时隔8年再次进行系统调整。新版目录结合疾病谱变化和临床用药需求，进一步补充慢性病、儿童、专科疾病及中医药优势病种用药，并对剂型、规格进行优化，提升药品在不同人群和医疗场景中的适用性。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU0572944931.SGD","09939","LU2039709279.SGD","LU0456846285.SGD","LU1720050803.USD","BK1589","02269","LU0051755006.USD","BK4531","ZLAB","LU0052750758.USD","LU0140636845.USD","LU1880383366.USD","09688","BK1574","LU0348766576.USD","02268","159938","LU0348767384.USD","LU0516423174.USD","LU2045819591.USD","LU0359202008.SGD","03347","BK4585","LU0856984785.SGD","KURE","BK1515","LU0588546209.SGD","LU2328871848.SGD","LU1303224171.USD","02359","BK4526","LU1794554557.SGD","LU0181495838.USD","LU0516422952.EUR","LU0516422440.USD","LU0039217434.USD","IE00B0JY6N72.USD","LU2488822045.USD","06160","BK1583","LU0326950275.SGD","LU1770034418.SGD","LU2242644610.SGD","SG9999002562.SGD","LU0823426308.USD","LU0043850808.USD","LU0327786744.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657602436","title":"药明生物早盘涨近6% 拟收购创胜医药位于杭州的工艺开发与生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2657602436","media":"新浪港股","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657602436?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:06","pubTimestamp":1786068360,"startTime":"0","endTime":"0","summary":"模拟交易客户端药明生物早盘涨近6%，截至发稿，股价上涨5.70%，现报43.74港元，成交额6.16亿港元。8月7日，据药明生物官微消息，药明生物宣布与创胜医药达成协议，公司拟收购创胜医药位于中国杭州的工艺开发与生产基地。该基地将增强药明生物一体化服务能力，以满足客户迅速增长的项目需求，预计该交易将于2026年第三季度完成。药明生物首席执行官陈智胜博士表示，收购进一步增强了药明生物覆盖原液开发与生产及制剂生产的端到端服务能力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-07/doc-inimmyer3383959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0181495838.USD","159938","LU0348825331.USD","LU0823426480.USD","LU0819121731.USD","LU0417516902.SGD","LU0348735423.USD","BK1589","LU0051755006.USD","LU0588546209.SGD","LU1794554557.SGD","SG9999002562.SGD","LU0708995583.HKD","BK1574","09939","02269","BK1521","LU0516422440.USD","LU0823426308.USD","LU0516422952.EUR","LU0516423091.SGD","BK1141","LU2039709279.SGD","LU1242518931.SGD","BK1161","LU3063872942.SGD","LU1242518857.USD","LU0327786744.USD","BK1515","LU0979878070.USD","LU0039217434.USD","LU0052750758.USD","BK1610","LU0572944931.SGD","BK1576","IE00B0JY6N72.USD","LU0856984785.SGD","LU0307460666.USD","LU0417516738.SGD","LU0516422366.SGD","KURE","LU0516423174.USD","LU0359201612.USD","LU0140636845.USD","LU0320764599.SGD","LU0326950275.SGD","LU1880383366.USD","SG9999002463.SGD","LU0043850808.USD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657266062","title":"港股异动 | 药明生物(02269.HK)涨超4% 拟收购创胜医药位于杭州的工艺开发与生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2657266062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657266062?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:52","pubTimestamp":1786067549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","LU0326950275.SGD","LU2039709279.SGD","IE00B0JY6N72.USD","LU0359202008.SGD","LU0051755006.USD","LU0417516738.SGD","LU0140636845.USD","BK1141","LU0823426308.USD","LU0856984785.SGD","LU0516422366.SGD","LU0708995583.HKD","LU0516422952.EUR","SG9999002463.SGD","BK1574","LU0516423174.USD","SG9999002562.SGD","LU0417516902.SGD","LU0348735423.USD","LU3063872942.SGD","LU0516422440.USD","LU0823426480.USD","KURE","LU0307460666.USD","LU0359201612.USD","02269","BK1610","LU0320764599.SGD","LU0348825331.USD","LU0979878070.USD","09939","LU0039217434.USD","LU1688375341.USD","LU0043850808.USD","LU1720050803.USD","LU1880383366.USD","LU0327786744.USD","LU0456827905.SGD","LU1794554557.SGD","BK1161","LU0516423091.SGD","LU0456846285.SGD","LU0572944931.SGD","LU0588546209.SGD","BK1521","LU0819121731.USD","LU1242518857.USD","BK1515","LU0052750758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197374518","title":"异动解读｜药明生物盘中上涨3.19%，CXO板块持续走强叠加中期业绩预期催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1197374518","media":"行情直击","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197374518?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:44","pubTimestamp":1786067085,"startTime":"0","endTime":"0","summary":"8月7日，药明生物盘中上涨3.19%，报42.66港元/股，成交额2.21亿港元。消息面上，同业药明康德此前公布中期业绩表现强劲，上半年实现营业收入288.97亿元，同比增长38.93%，扣非净利润同比增长89.39%，带动CXO板块集体走强。当日板块内康龙化成涨5.63%、药明康德涨3.45%、药明合联涨2.71%，呈现普涨格局。此外，药明生物董事会已定于8月25日审议中期业绩，市场对业绩存在积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中上涨3.19%，CXO板块持续走强叠加中期业绩预期催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137245102","title":"药明生物更新7月股份变动月报，新增发行1,636,400股","url":"https://stock-news.laohu8.com/highlight/detail?id=1137245102","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137245102?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:15","pubTimestamp":1786025754,"startTime":"0","endTime":"0","summary":"药明生物技术有限公司于2026年8月6日发布的截至2026年7月31日的证券变动月报显示，公司注册股本维持6,000,000,000股普通股，面值合计50,000美元，较上月底无变化。报告期内，公司已发行股份由4,143,356,617股增至4,144,993,017股，净增1,636,400股。公司另披露购回股份共计39,842,500股，但截至7月末仍未注销，未影响当期已发行股份数量。同时，公司披露仍符合香港联合交易所有限公司公开发售股份持股量的相关规定，并确认所有本月发生的证券发行均已履行必要的内部决议程序及法定要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136026140","title":"异动解读｜药明生物盘中上涨3.1%，CXO板块延续强势及中期业绩预期催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1136026140","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136026140?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:14","pubTimestamp":1785986084,"startTime":"0","endTime":"0","summary":"8月6日，药明生物盘中上涨3.1%，报41.86港元/股，成交额6.78亿港元。消息面上，同业药明康德此前公布中期业绩表现强劲，上半年实现营业收入288.97亿元，同比增长38.93%，扣非净利润同比增长89.39%，带动CXO板块集体走强。药明生物董事会已定于8月25日审议中期业绩，市场对业绩存在积极预期。此外，机构研究指出CXO景气周期已逐步进入利润表兑现期，全球创新药一级市场上半年融资金额同比增长58.5%，行业景气度持续支撑板块估值修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中上涨3.1%，CXO板块延续强势及中期业绩预期催化","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591407","title":"【特约大V】邓声兴：美伊缓和油价暴泻，恒指望随外围强弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591407","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657591407?lang=zh_cn&edition=full","pubTime":"2026-08-05 10:46","pubTimestamp":1785897999,"startTime":"0","endTime":"0","summary":"美伊缓和油价暴泻，恒指望随外围强弹。基本面上，2025年全年收入达217.9亿元人民币，同比增长16.7%；毛利率大幅提升5个百分点至46%；公司拥有人应占纯利49.08亿元，同比大增46.3%。截至2025年底，未完成订单总量增至237亿美元，综合项目总数达945个，新签209个项目创历史新高。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987509","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRLL","WTIU","02833","82800","IEO","03115","SDOG","PXJ","DBC","PEJ","UGA","BNO","XES","HHImain","OILT","OILU","03419","DBE","USOI","KURE","OIH","HSI","OILK","VDE","SPXT","XLEX","MHImain","TPOR","PXE","VOOV","02359","03037","MCHmain","HSImain","USL","ERX","IXC","02269","DBO","UAE","DUG","USE","WEEI","DIG","FTXN","513600","07500","BWET","DRIP","GUSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589194","title":"港股异动 | CRO概念股涨幅居前 近期多家海外MNC与CXO披露中报盈喜并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656589194?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0327786744.USD","LU0516423091.SGD","LU0417516738.SGD","LU0348766576.USD","HK0000320223.HKD","LU0181495838.USD","HK0000306685.HKD","KURE","LU0572944931.SGD","02359","LU1720050803.USD","LU0359202008.SGD","LU0348825331.USD","LU2045819591.USD","LU0708995583.HKD","HK0000320264.USD","LU1880383366.USD","LU0140636845.USD","LU0348735423.USD","01548","BK1141","BK1589","HK0000306701.USD","06821","LU0823426308.USD","LU1688375341.USD","LU0052750758.USD","LU3063872942.SGD","LU0516422366.SGD","LU0043850808.USD","LU1242518931.SGD","BK1610","LU0819121731.USD","02269","BK1583","LU0823426480.USD","LU0307460666.USD","BK1576","LU0051755006.USD","LU0588546209.SGD","LU2125910500.SGD","BK1521","LU0456827905.SGD","LU1242518857.USD","LU0516422952.EUR","LU2242644610.SGD","LU0326950275.SGD","BK1191","LU0039217434.USD","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656158919","title":"港股异动 | CRO概念股涨幅居前 近期多家海外MNC与CXO披露中报盈喜并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656158919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656158919?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨11.05%，报180.9港元；金斯瑞生物科技涨10.18%，报17.96港元；凯莱英涨7.71%，报117.4港元；药明生物涨3.92%，报40.34港元。消息面上，药明康德公告称，上半年公司实现营业收入288.97亿元，同比增长38.93%；归母净利润110.8亿元，同比增长29.43%。值得注意的是，近期已有多家多家海外MNC与CXO披露中报盈喜并上调全年指引。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348766576.USD","LU0327786744.USD","02359","WX","LU0516422440.USD","LU1720050803.USD","LU0348767384.USD","06821","LU0359202008.SGD","SG9999002463.SGD","LU1242518931.SGD","LU1688375341.USD","LU0348825331.USD","KCAI","LU1794554557.SGD","BK1191","01548","LU0856984785.SGD","LU1046422090.SGD","VXUS","BK4588","LU0043850808.USD","BK1576","HK0000306685.HKD","LU1242518857.USD","02269","LU0417516738.SGD","LU0979878070.USD","LU0052750758.USD","LU0140636845.USD","LU0456827905.SGD","KURE","HK0000306701.USD","BK1141","LU0588546209.SGD","LU0823426480.USD","BK1610","BK1521","LU0708995583.HKD","BK1589","LU0039217434.USD","BK1583","LU0516423174.USD","LU3063872942.SGD","LU0456846285.SGD","LU0516422952.EUR","CXO","LU0417516902.SGD","BK4585","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656863415","title":"药明康德（02359）中期业绩提振医药外包概念股 凯莱英（06821）涨7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656863415","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656863415?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:36","pubTimestamp":1785807412,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明康德 中期业绩强劲，推动股价大涨逾14%，同步提振医药外包概念股，凯莱英涨7.98%，康龙化成涨7.58%，泰格医药涨5.62%，金斯瑞生物科技涨6.01%，药明生物涨4.95%，昭衍新药涨4.93%，维亚生物涨1.96%。据药明康德公告，上半年公司实现营业收入288.97亿元，同比增长38.93%；归属于上市公司股东的净利润110.8亿元，同比增长29.43%；扣非净利润105.72亿元，同比增长89.39%。公司计划上半年向全体股东每10股派发现金红利5.10元。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987415","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","LU0611395673.USD","BK1576","LU0979878070.USD","LU0307460666.USD","IE00B5MMRT66.SGD","BK1515","HK0000306685.HKD","KURE","LU0320764599.SGD","LU0856984785.SGD","LU1688375341.USD","BK1610","03759","IE00BPRC5H50.USD","BK1191","002821","HK0000320264.USD","LU2488822045.USD","LU1046422090.SGD","LU1997245094.SGD","LU2242644610.SGD","LU0348766576.USD","LU0456842615.SGD","01548","159938","09939","06127","02269","BK1589","603259","01873","LU0823426308.USD","LU1251922891.USD","LU0039217434.USD","LU0516422440.USD","03347","HK0000320223.HKD","LU0359202008.SGD","LU1808992512.USD","LU0700851271.USD","LU2045819591.USD","LU0181495838.USD","LU2495084118.USD","06821","BK1583","BK0239","LU0348767384.USD","SG9999002562.SGD","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656816586","title":"港股开盘 | 恒指高开0.31% 医药CXO板块走强 药明康德(02359)涨近10%、中际旭创(03308)涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656816586","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656816586?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:34","pubTimestamp":1785807258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月4日，恒生指数高开0.31%，报26090.98点；恒生科技指数涨0.30%，报4890.34点。医药CXO板块大幅走强，药明康德涨近10%，药明生物涨超3%，昭衍新药涨近6%，凯莱英涨超5%，泰格医药涨近4%。药明康德此前披露半年报，上半年营收288.97亿元同比增长38.93%，并全面上调全年业绩指引。光通信板块活跃，中际旭创涨超9%。云计算及AI应用板块走高，金山云涨超5%。受隔夜美股科技板块走强带动，港股今日延续高开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603127","LU0039217434.USD","LU1046422090.SGD","LU3063872942.SGD","07300","03417","IE00B0JY6N72.USD","03067","02800","09067","03308","300347","MCHmain","03347","KURE","BK1191","07500","02269","07552","BK1122","03033","LU0326950275.SGD","300308","09115","02833","LU2125910500.SGD","03037","03088","LU0181495838.USD","LU0516423091.SGD","LU0572944931.SGD","LU0823426480.USD","03032","07226","BK1610","SG9999002562.SGD","LU2039709279.SGD","LU1242518931.SGD","BK1583","603259","LU0516422366.SGD","LU0359202008.SGD","513600","002821","LU0359201612.USD","WXXWY","LU0456846285.SGD","LU0823426308.USD","09088","02837","LU0516422440.USD","BK1141","HHImain","LU1880383366.USD","LU0327786744.USD","LU0417516738.SGD","LU0516422952.EUR","LU0043850808.USD","LU0320764599.SGD","LU0052750758.USD","LU0348767384.USD","LU0348735423.USD","BK1576","LU0140636845.USD","07200","BK1533","BK1589","LU0348766576.USD","LU0516423174.USD","HSI","LU1720050803.USD","BK1249","LU2045819591.USD","LU0307460666.USD","HSTECH","LU0819121731.USD","LU1242518857.USD","LU0417516902.SGD","LU1794554557.SGD","LU0856984785.SGD","LU0708995583.HKD","02359","03419","LU0348825331.USD","82800","06821","03423","SG9999002463.SGD","LU0588546209.SGD","06127","83115","BK1149","LU2242644610.SGD","03115","LU0979878070.USD","BK1521","LU0051755006.USD","LU0456827905.SGD","LU1688375341.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172498660","title":"异动解读｜药明生物盘中上涨4.85%，CXO板块集体走强带动","url":"https://stock-news.laohu8.com/highlight/detail?id=1172498660","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172498660?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:32","pubTimestamp":1785807156,"startTime":"0","endTime":"0","summary":"8月4日，药明生物盘中上涨4.85%，报40.22港元/股，成交额1.8亿港元。消息面上，生命科学工具和服务板块集体走强，同业药明康德涨12.28%、康龙化成涨6.78%、药明合联涨4.79%，CXO板块呈现普涨格局。此外，公司董事会已定于8月25日审议中期业绩，市场对业绩存在期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中上涨4.85%，CXO板块集体走强带动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129717447","title":"异动解读｜药明生物盘中上涨3.07%，报38.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129717447","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129717447?lang=zh_cn&edition=full","pubTime":"2026-07-31 13:20","pubTimestamp":1785475247,"startTime":"0","endTime":"0","summary":"7月31日，药明生物盘中上涨3.07%，报38.96港元/股，成交额3.99亿港元。药明生物所在的生命科学工具和服务行业中，板块整体走强，个股中，英矽智能涨9.94%，金斯瑞生物科技涨6.16%，药明康德涨2.16%，晶泰控股涨8.23%，药明合联涨1.57%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333030","title":"医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333030","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655333030?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:18","pubTimestamp":1785464310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念整体回暖，截止发稿，昭衍新药 涨4.51%，康龙化成涨3.10%，金斯瑞生物科技涨2.97%，凯莱英涨2.77%，药明生物涨2.75%，药明康德涨2.60%，泰格医药涨1.39%。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","159938","LU0320764599.SGD","LU0417516738.SGD","LU0307460666.USD","BK1589","LU0359202008.SGD","LU0823426480.USD","03347","603127","LU0359201612.USD","LU0181495838.USD","LU0823426308.USD","LU1794554557.SGD","LU0140636845.USD","03759","LU0348825331.USD","LU0588546209.SGD","06127","LU1720050803.USD","LU0327786744.USD","KURE","LU0708995583.HKD","09939","02269","LU0348735423.USD","HK0000306685.HKD","01548","LU1046422090.SGD","BK1191","LU1242518931.SGD","LU0051755006.USD","LU0348766576.USD","LU2045819591.USD","SG9999002463.SGD","300759","02359","LU0819121731.USD","LU3063872942.SGD","06821","LU0516422366.SGD","LU1880383366.USD","BK1521","BK1141","LU0516423091.SGD","BK1574","HK0000306701.USD","LU0516422440.USD","LU1242518857.USD","LU0456827905.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148031940","title":"异动解读｜药明生物盘中下跌3.15%，报38.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148031940","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148031940?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:27","pubTimestamp":1785378460,"startTime":"0","endTime":"0","summary":"7月30日，药明生物盘中下跌3.15%，报38.14港元/股，成交额2.73亿港元。药明生物所在的生命科学工具和服务行业中，板块整体走弱，个股中，英矽智能跌2.71%，药明康德跌2.14%，晶泰控股跌1.47%，金斯瑞生物科技跌0.92%，药明合联跌4.53%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832949","title":"港股开盘向好 恒指高开0.7% 理想汽车-W（02015）涨4.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832949","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832949?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:25","pubTimestamp":1785288345,"startTime":"0","endTime":"0","summary":"北京汽车高开2.33%，惟公司发盈警，预期将录得截至2026年6月30日止六个月归属于公司权益持有人的净亏损约为15.5亿元至16.5亿元人民币，较2025年同期出现由盈转亏的变动。该公司认为，由于2026年上半年国内汽车行业竞争激烈，该公司销量未达预期，叠加原材料上涨以及加大市场投入等因素影响，综合导致归属于公司权益持有人的净亏损。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986989","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNVGY","LU0348784397.USD","LU0823426308.USD","LU1224709979.USD","SGXZ62798434.SGD","LU0650527681.SGD","SGXZ86797644.SGD","LU1046422090.SGD","LU0345780950.USD","BK1141","LU0140636845.USD","LU1102505762.USD","LU1366334578.USD","BK1172","03067","LU0181495838.USD","LU1688375341.USD","HK0000320264.USD","LU0128522157.USD","LU1719994722.HKD","LU1785774172.SGD","LU2125910500.SGD","SG9999004220.SGD","LU0307460666.USD","09088","ZTO","02313","HHImain","LU0856984785.SGD","BK1226","LU0244354667.USD","LU0588546209.SGD","LU1023057109.AUD","LU1048596156.SGD","07200","LU0463099449.HKD","LU0651946864.USD","03088","BK1591","03419","02833","BK1521","IE0032431581.USD","LU0029875118.USD","IE00BMCWC346.EUR","LU0862451753.SGD","LU2097828631.EUR","BK1502","02837","IDRV","LU1051768304.USD","07552","LU1634259391.SGD","LU2399975544.HKD","HK0000306685.HKD","IE00BZ08YR35.GBP","LU0456827905.SGD","BK1212","BK1161","LU0251144936.SGD","BK1592","LU0561508036.HKD","LU0572940350.SGD","LU0737861699.HKD","BK1227","LU1211504680.USD","01378","LU1242518857.USD","LU1251922891.USD","BK1526","IE00BVYPNP33.GBP","LU0310800965.SGD","LU2488822045.USD","IE0008368742.USD","BK1576","LU0327786744.USD","LU0516422440.USD","LU1235295612.USD","07300","LU0572944931.SGD","LU0634319403.HKD","09858","LU0149534421.HKD","LU0594300179.USD","HSTECH","LU0441854154.USD","LU1188198961.HKD","LU1303224171.USD","LI","LU1515016050.SGD","LU2097828557.USD","LU0405327148.USD","LU0320764755.SGD","LU2929501877.USD","SCHYY","LU0708995583.HKD","LU0173614495.USD","BK1594","LU0979878070.USD","LU0791591158.USD","LU0043850808.USD","BK1607","LU0791590937.USD","LU0228367735.SGD","LU0972618739.USD","LU0607220059.USD","LU0819121731.USD","09115","LU0417516738.SGD","02015","LU0359201885.HKD","LU2097828474.EUR","LU0359202008.SGD","TCHI","IE00BVYPNQ40.USD","SG9999006597.SGD","BK1589","LU0405327494.USD","LU0315179316.USD","LU1522347837.USD","LU2328871848.SGD","HK0001040143.USD","LU0516422366.SGD","LU0672654166.SGD","HK0000306701.USD","BK1119","LU0823426480.USD","LU1969619763.USD","LU0469268626.HKD","03423","LU0320764599.SGD","LU1166156734.SGD","BK1610","01958","IE00BYV24P56.USD","07226","IE00B19Z5X02.USD","LU0348827113.USD","LU1115378108.SGD","SG9999001226.SGD","MCHmain","03033","LU0516423174.USD","HK0001040168.HKD","LU1366334651.USD","BK1193","LU1224444064.USD","WXXWY","IE0034224299.USD","80992","IE00BGHQDM52.EUR","LU1961090484.USD","IE00B0JY6N72.USD","07500","LU0051755006.USD","LU1048588211.SGD","LU1267930227.SGD","LU1831875114.USD","LU1808992512.USD","LU0326950275.SGD","LU0543330483.HKD","LU0630314457.HKD","LU0702159699.USD","01928","BK1541","LU0314109678.HKD","LU1282651048.USD","SG9999002562.SGD","LU0417516571.SGD","BK1539","601857","BK1237","LU1794554557.SGD","LU2097828714.EUR","LU0163747925.USD","LU0293314216.USD","IE0008369823.USD","LU0315178854.USD","IE00B031J352.USD","LU1497733557.USD","LU2187417386.USD","IE00B543WZ88.USD","LU0039217434.USD","LU2097828805.USD","LU0417516902.SGD","LU0588545904.SGD","09067","LU0640798160.USD","LU0828237940.HKD","LU0052756011.USD","06862","SG9999002463.SGD","LU1880383366.USD","82800","LU2351347302.SGD","LU1328277881.USD","03115","LU0821914370.USD","LU0264606111.USD","BK1604","LU0048597586.USD","KURE","LU0605514214.HKD","LU1634259557.SGD","03037","IE00BZ08YT58.USD","LU0049112450.USD","02057","688235","LU0540923850.HKD","LU0516423091.SGD","IE00BQJZWZ67.USD","LU1813983027.USD","SG9999014674.SGD","LU1720050803.USD","LU0588545730.USD","BK1583","LU0348735423.USD","LU0675040207.SGD","LU0862451837.USD","SG9999003461.SGD","LU1102505929.USD","BK1588","03417","LU0588545490.SGD","LU0052750758.USD","HK0000320223.HKD","LU0348783233.USD","83115","LU2045819591.USD","LU0865486749.SGD","513600","LU1497733631.SGD","LU0890818403.SGD","BK1151","IE0031814852.USD","LU0345781412.USD","LU1242518931.SGD","IE00BWDBJ730.SGD","BK1500","LU1675838814.USD","SG9999001093.SGD","BK1575","LU3063872942.SGD","ONC","BK1528","HSI","02800","LU0287142896.SGD","LU0348805143.USD","00992","LU0572939691.SGD","LU1770034418.SGD","LU0348825331.USD","LU0516422952.EUR","LU2242644610.SGD","LU1282651121.HKD","BK1587","LU0594300419.USD","IE00BZ08YS42.EUR","LU0072462343.USD","LU0348783662.USD","LU2293587155.HKD","03032","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU0128525689.USD","LU0211977185.USD","LU0611395673.USD","06160","IE00B031HY20.USD","LU0359201612.USD","BK1175","02269","LU0456846285.SGD","LU1497734951.SGD","LU2039709279.SGD","BK1233","IE00B29SXG58.USD","IE0003895053.USD","00857"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","601211","LU0348784397.USD","02269","HK0000165453.HKD","02142","LU0561508036.HKD","01177","LU0307460666.USD","LU2242644610.SGD","02616","01801","LU0051755006.USD","LU0979878070.USD","BK1588","LU1251922891.USD","LU0417516738.SGD","LU2476274308.USD","02611","LU1008478684.HKD","BK1141","CDMO","06160","BK1147","KCE","LU0588546209.SGD","SG9999002463.SGD","BK1574","LU0181495838.USD","BK1564","BK1610","LU0052750758.USD","06185","LU1328277881.USD","LU1719994722.HKD","LU1720050803.USD","09995","BK1583","IE00B543WZ88.USD","LU0634319403.HKD","LU0359202008.SGD","01093","IE00B5MMRT66.SGD","09688","09926","161027","KURE","LU0067412154.USD","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU2399975544.HKD","LU0634319403.HKD","09996","LU0588546209.SGD","02096","06996","LU0348783233.USD","LU0856984785.SGD","06078","09926","LU2039709279.SGD","09966","01177","02162","02269","BK1521","06990","02596","BK1219","BK1587","LU1813983027.USD","02273","159938","LU1720050803.USD","KURE","03692","01276","01951","LU2476274308.USD","01548","00013","LU2097828714.EUR","HK0000165453.HKD","LU2328871848.SGD","01093","01801","HK0000320223.HKD","02268","09939","KCE","03329","03759","01530","01952","06821","LU0572944931.SGD","LU1880383366.USD","LU0417516571.SGD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011748","title":"普洛药业最新公告：控股子公司与药明生物、多宁生物签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654011748?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:51","pubTimestamp":1785149471,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司控股子公司浙江安特禹泰生物技术有限公司与上海药明生物技术有限公司、上海多宁生物科技股份有限公司签署《战略合作框架协议》，三方拟建立长期战略合作关系，推动生物大分子药物管线开发、产业化能力建设及供应链体系完善。协议有效期五年，不涉及具体项目和金额，对公司本年度经营业绩不构成重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700027363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0456827905.SGD","SG9999002562.SGD","LU0359202008.SGD","LU0456846285.SGD","LU1242518857.USD","BK0239","BK1589","LU3063872942.SGD","LU0417516738.SGD","LU0516422440.USD","LU0052750758.USD","LU0327786744.USD","LU0516423091.SGD","LU0039217434.USD","LU0819121731.USD","LU0588546209.SGD","LU0708995583.HKD","BK1576","LU0516423174.USD","BK1141","LU0051755006.USD","LU0856984785.SGD","IE00B0JY6N72.USD","LU0823426480.USD","BK1521","LU0181495838.USD","LU0348825331.USD","LU0307460666.USD","LU0516422366.SGD","LU0320764599.SGD","LU0823426308.USD","000739","LU1794554557.SGD","LU0417516902.SGD","LU0326950275.SGD","LU0572944931.SGD","LU0348735423.USD","LU1688375341.USD","LU2039709279.SGD","SG9999002463.SGD","LU0140636845.USD","LU0043850808.USD","KURE","LU1720050803.USD","BK1610","LU0359201612.USD","LU0516422952.EUR","BK0188","LU0979878070.USD","02269"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.0947},{"period":"1month","weight":0.1251},{"period":"3month","weight":0.267},{"period":"6month","weight":0.0982},{"period":"1year","weight":0.3087},{"period":"ytd","weight":0.3162}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":0.0865},{"period":"3month","weight":-0.0327},{"period":"6month","weight":-0.0388},{"period":"1year","weight":0.0249},{"period":"ytd","weight":-0.0039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.666667,"avgChangeRate":0.061606},{"month":7,"riseRate":0.7,"avgChangeRate":0.085288},{"month":8,"riseRate":0.6,"avgChangeRate":0.034042},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}